BYL719, BYL719, BYL719, BYL719, BYL719
CBYL719F12202
Phase 2 small_molecule active
Quick answer
BYL719, BYL719, BYL719, BYL719, BYL719 for PIK3CA-Related Overgrowth Spectrum (PROS) is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- PIK3CA-Related Overgrowth Spectrum (PROS)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active